SB202190

SB202190 is an inhibitor of p38 MAPK used in studies of MAPK / ERK Signaling and Immune Signaling and related signaling programs. It is especially relevant in apoptosis, autophagy, and cancer models, where defined compound exposure can be linked to mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-mediated signaling and inflammatory effector responses.

By inhibiting p38 MAPK, SB202190 can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-mediated signaling and inflammatory effector responses. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In apoptosis, autophagy, and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving p38 MAPK
• Pathway perturbation studies connected to MAPK / ERK Signaling and Immune Signaling and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, SB202190 is appropriate when a defined chemical perturbant is needed to connect p38 MAPK with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, autophagy, and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.